Skip to main content

Geron

Geron Corporation is an American commercial-stage biopharmaceutical enterprise developing first-in-class telomerase inhibitor therapeutics for hematologic malignancies. The company commercializes Rytelo (imetelstat), an FDA-approved telomerase inhibitor designed for the treatment of adult patients with lower-risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia. Principal revenues derive from commercial product sales of Rytelo prescription therapies directly to specialty pharmaceutical distributors and hospital networks, alongside strategic licensing royalties. Core end markets encompass hematology-oncology clinics, specialized cancer centers, and prescription anemia patients across North America and international markets. Geron holds a market-leading pioneer position as the developer of the world's first approved telomerase inhibitor therapy in oncology. The corporation is headquartered in Foster City, California, and its common stock trades on the Nasdaq Global Select Market.

2 of the funds FundTelligence covers report a position in Geron.

Legal name
Geron Corp
Sector
Health Care
Country
United States
Funds holding it
2

Funds holding Geron

Loading...